167 results on '"Slomovitz B"'
Search Results
2. Disparities in care among patients with low-grade serous ovarian carcinoma
3. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
4. BIOMARKER PREDICTION OF OUTCOME VARIES BY RACE IN UTERINE SEROUS CARCINOMA: EP483
5. ASSOCIATIONS BETWEEN THROMBOCYTOSIS, PREDICTIVE BIOMARKERS, AND SURVIVAL OUTCOMES IN UTERINE SEROUS CARCINOMA: EP482
6. 240 First year experience of hereditary testing in gynecological cancer patients in a clinical setting in the bahamas
7. 48 Variations in endometrial cancer risk and histologic distribution by caribbean nativity
8. EPV107/#258 ENGOT-EN11/GOG-3053/KEYNOTE-B21: phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer
9. EPV255/#120 Tisotumab vedotin vs investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovatv 301/ENGOT-CX12/GOG-3057, trial in progress)
10. 185 ENGOT-en11/GOG-3053/KEYNOTE-B21: phase 3 study of pembrolizumab or placebo + adjuvant chemotherapy ± radiotherapy for high-risk endometrial cancer
11. 40 InnovaTV 301/ENGOT-cx12/GOG-3057: tisotumab vedotin vs investigator’s choice chemo in second- or third-line recurrent or metastatic cervical cancer
12. 820TiP ENGOT-EN6/GOG-3031/NSGO-CTU-RUBY part 2: A phase III, randomized, double-blind, study of dostarlimab + carboplatin-paclitaxel followed by dostarlimab + niraparib versus placebo (PBO) + carboplatin-paclitaxel followed by PBO in recurrent or advanced endometrial cancer (EC)
13. 818TiP Balstilimab alone or in combination with zalifrelimab as second-line treatment for patients with previously treated recurrent/metastatic cervical cancer (R/M CC): A randomized, placebo-controlled phase II trial (RaPiDS/GOG-3028)
14. 15 Randomized double-blind placebo controlled trial of frontline maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: efficacy assessment in BRCA1/2-wt patients
15. 358 Phase 3 trial of tumor treating fields concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: ENGOT-ov50/GOG-329/INNOVATE-3
16. Genetic profiling characteristics of patients with low-grade serous carcinoma of the ovary in a racially diverse population
17. Phase II study of durvalumab alone or in combination with ADXS11-001 (AXAL) in recurrent/persistent or metastatic cervical cancer
18. Somatic mutation detection by cervicovaginal swab as a potential screening test for endometrial cancer: A pilot study
19. Targeting ovarian and breast cancers through phosphatase inhibition
20. Validation of sentinel lymph biopsy in patients with early stage vulvar cancer: A prospective trial of 1552 women (GROINSS-V II/GOG270)
21. Radiotherapy as an alternative treatment for inguinofemoral lymphadenectomy in vulvar cancer patients with a metastatic sentinel node: Results of GROINSS-V II
22. Prognostic implications of the addition of nodal status to uterine cervix cancer staging
23. Randomized double-blind placebo-controlled trial of primary maintenance vigil immunotherapy (VITAL study) in stage III/IV ovarian cancer: Efficacy assessment in BRCA1/2-wt patients
24. Radiotherapy instead of inguinofemoral lymphadenectomy in vulvar cancer patients with a metastatic sentinel node: results of GROINSS-V II
25. EP482 Associations between thrombocytosis, predictive biomarkers, and survival outcomes in uterine serous carcinoma
26. EP483 Biomarker prediction of outcome varies by race in uterine serous carcinoma
27. 240 First year experience of hereditary testing in gynecological cancer patients in a clinical setting in the bahamas
28. 48 Variations in endometrial cancer risk and histologic distribution by caribbean nativity
29. A comparison of molecular tumor profiles from hispanic and non-hispanic women with ovarian cancer
30. Therapeutic efficacy of vocimagene amiretrorepvec (Toca 511) prodrug activator gene therapy in peritoneal carcinomatosis models of ovarian cancer
31. Disparities in the evolution of polypharmacy among women with ovarian cancer
32. Is there a role for for minnelide in uterine serous cancers?
33. Preparation in the Business and Practice of Medicine: Perspectives from Graduates and Fellowship Directors
34. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
35. A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer
36. Vocimagene amiretrorepvec (Toca 511) for prodrug activator gene therapy in ovarian cancer models
37. Exposure to risk factors for cervical and anal dysplasia in transgender men and women: A retrospective chart review
38. Antioxidant gene expression program is deregulated early in serous ovarian cancer
39. Pseudotyped retroviral replicating vectors for combination prodrug activator gene therapy of ovarian cancer
40. Retrospective evaluation of the accuracy of robotic sentinel lymph node detection (RSLND) using indocyanine green (ICG) dye for endometrial and cervical malignancies
41. Initiation of a dysplasia clinic within a division of gynecologic oncology (DGO) at a tertiary cancer center
42. The obese endometrial cancer patient: how do we effectively improve morbidity and mortality in this patient population?
43. Immunohistochemical expression of estrogen and progesterone receptors and clinical outcomes among uterine and nonuterine leiomyosarcomas
44. Impact of Adjuvant Therapy on Patient Survival in Stage I/II High-Risk Endometrial Cancers
45. 931O - A phase IIa study of tisotumab vedotin (HuMax®-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer
46. The Comparison Between Reporting Doses per GEC ESTRO and Estimation From Deformable Dose Accumulation
47. Can negative biomarkers be helpful? A novel combination test to predict non-response to inhibition of the mammalian target of rapamycin (mTOR) pathway in endometrial cancer
48. Establishing stage of learning curve for robotic surgery: Institutional cumulative sum of failure (CUSUM) analysis within division of gynecologic oncology
49. The search continues: Looking for predictive biomarkers for response mTOR inhibition in endometrial cancer.
50. A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.